Fragment-based virtual screening discovers potential new Plasmodium PI4KIIIβ ligands

Type III beta phosphatidylinositol 4-kinase (PI4KIIIβ) is the only clinically validated drug target in Plasmodium kinases and therefore a critical target in developing novel drugs for malaria. Current PI4KIIIβ inhibitors have solubility and off-target problems. Here we set out to identify new Plasmo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibezim, Akachukwu, Madukaife, Mbanefo S., Osigwe, Sochi C., Engel, Nadja, Karuppasamy, Ramanathan, Ntie-Kang, Fidele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944149/
https://www.ncbi.nlm.nih.gov/pubmed/35331319
http://dx.doi.org/10.1186/s13065-022-00812-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944149/
https://www.ncbi.nlm.nih.gov/pubmed/35331319
http://dx.doi.org/10.1186/s13065-022-00812-2

Ejemplares similares